Wednesday, July 8, 2026

Patent intelligence · US

US 11981739

Chimeric antigen receptor specific for interleukin-23 receptor

granted A61KA61K2039/505A61K2239/31A61K2239/38
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 18
Applicant portfolio 192
Patent details — US 11981739
Jurisdiction
US
Status
granted
Grant date
May 14, 2024
Expiration
May 9, 2044
Claims
20
CPC classes
A61K, A61K2039/505, A61K2239/31, A61K2239/38
View on Google Patents ↗

Quick answer

US 11981739 (Chimeric antigen receptor specific for interleukin-23 receptor) is held by SANGAMO THERAPEUTICS FRANCE. Status: granted. Granted May 14, 2024. Expires May 9, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61K, A61K2039/505, A61K2239/31, A61K2239/38, A61K40/11, A61K40/22

More from SANGAMO THERAPEUTICS FRANCE

Related pharmaceutical patents in our USPTO index.

  1. US 12318427

    Methods and compositions for modulation of tau proteins

    Sangamo Therapeutics, Inc. · Expires May 29, 2045

    granted
  2. US 12139517

    Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof

    Sangamo Therapeutics, Inc. · Expires Nov 7, 2044

    granted
  3. US 12043650

    Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene

    Sangamo Therapeutics, Inc. · Expires Jul 18, 2044

    granted
  4. US 11981967

    Engineering AAV

    Sangamo Therapeutics, Inc. · Expires May 9, 2044

    granted
  5. US 11920169

    Compositions for linking DNA-binding domains and cleavage domains

    Sangamo Therapeutics, Inc. · Expires Feb 29, 2044

    granted
  6. US 11898158

    Methods and compositions for the treatment of lysosomal storage diseases

    Sangamo Therapeutics, Inc. · Expires Feb 8, 2044

    granted
  7. US 11884930

    Method of inactivating a glucocorticoid receptor gene in an isolated cell

    Sangamo Biosciences, Inc. · Expires Jan 25, 2044

    granted

Frequently asked questions

What is US patent 11981739?

US 11981739 (Chimeric antigen receptor specific for interleukin-23 receptor) is held by SANGAMO THERAPEUTICS FRANCE. Status: granted. Granted May 14, 2024. Expires May 9, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11981739?

SANGAMO THERAPEUTICS FRANCE is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 192 pharmaceutical patents for this assignee.

When does US 11981739 expire?

Our index shows an expiration date of May 9, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.